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a b s t r a c t 
Poly( γ-glutamic acid) ( γ-PGA) nanoparticles (NPs) carrying antigens have been shown to induce potent
antigen-speciﬁc immune responses. However, in vivo delivery of γ-PGA NPs to dendritic cells (DCs), a key
regulator of immune responses, still remains unclear. In this study, γ-PGA NPs were examined for their
uptake by DCs and subsequent migration from the skin to the regional lymph nodes (LNs) in mice. After
subcutaneous injection of ﬂuorescein 5-isothiocyanate (FITC)-labeled NPs or FITC-ovalbumin (OVA)-carrying
NPs (FITC-OVA-NPs), DCs migrated from the skin to the LNs and maturated, resulting in the upregulation of
the costimulatory molecules CD80 and CD86 and the chemokine receptor CCR7. However, the migrated DCs
were not detected in the spleen. FITC-OVA-NPs were found to be taken up by skin-derived CD103 + DCs, and
the processed antigen peptides were cross-presented by the major histocompatibility complex (MHC) class
I molecule of DCs. Furthermore, signiﬁcant activation of antigen-speciﬁc CD8 + T cells was observed in mice
immunized with OVA-carrying NPs (OVA-NPs) but not with OVA alone or OVA with an aluminum adjuvant.
The antigen-speciﬁc CD8 + T cells were induced within 7 days after immunization with OVA-NPs. Thus, γ-PGA
NPs carrying various antigens may have great potential as an antigen-delivery system and vaccine adjuvant
in vivo. 






















 1. Introduction 
Vaccines are an effective tool for modulating host immune
responses to speciﬁc antigens, especially microbial pathogen-
associated antigens. However, immunization with a protein or pep-
tide antigen alone in the absence of adjuvants often fails to induce
effective immune responses [ 1 ]. Adjuvants enhance the immuno-
genicity of vaccines by different mechanisms [ 2 ]. Novel vaccine ad-
juvants and particle-based antigen delivery systems are being eval-
uated in a variety of vaccines, expecting potent adaptive immune
responses [ 3 , 4 ]. Cellular immunity is required to remove intracellular
pathogens such as tuberculosis and malaria, while humoral immu-
nity plays a central role in neutralizing extracellular microorganisms* Corresponding author at: Division of Antiviral Chemotherapy, Center for Chronic 
Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, 
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Open access under CC BY-NC-ND lic[ 4 , 5 ]. Aluminum-based compounds are used as adjuvants in humans
because of their safety. Aluminum-based adjuvants can elicit antigen-
speciﬁc humoral immunity, yet they hardly induce cellular immunity
[ 6 ]. Thus, the activation of cellular immune responses is an important
subject for the next generation of vaccines. 
Dendritic cells (DCs) are antigen-presenting cells (APCs) charac-
terized by a unique capacity to stimulate na ¨ıve T cells and initiate
innate immune responses into adaptive immune responses [ 7 , 8 ]. Im-
mature DCs develop into mature DCs with the upregulation of major
histocompatibility complex (MHC) and costimulatory molecule ex-
pression and inﬂammatory cytokine secretion, when the cells are
exposed to antigens. DCs can present the uptake antigens along
with the MHC class I molecule to CD8 + T cells through the antigen
cross-presentation pathway [ 9 ]. Immature DCs recognize pathogen-
associated molecules via a series of pattern-recognition receptors, in-
cluding the Toll-like receptors and inﬂammatory components [ 7 , 10 ].
Immature DCs reside in peripheral tissues, where they capture and
process antigens. Subsequently, DCs migrate to the secondary lym-
phoid organs, present the processed antigen peptides to na ¨ıve T cells,
and induce adaptive immune responses [ 11 ]. Thus, the stimulation
of DCs through antigen uptake is important for inducing effective
immune responses. ense.























































eBiodegradable nanoparticles (NPs) composed of poly( γ-glutamic 
cid) ( γ-PGA) with l -phenylalanine ethyl ester have been shown to 
enerate antigen-speciﬁc cellular and humoral immune responses 
fter immunization with various antigens [ 12 , 13 ]. γ-PGA is water- 
oluble, biodegradable, edible, and non-toxic polyamino acids pro- 
uced by certain strains of bacilli. γ-PGA NPs have a capacity of immo- 
ilizing various proteins, peptides, and chemicals onto their surfaces 
nd / or encapsulating these substances into the particles [ 14 ]. γ-PGA 
Ps could induce a signiﬁcantly higher level of antigen-speciﬁc adap- 
ive immune responses in mice and monkeys than antigens alone or 
ntigens with other common adjuvants [ 15 –17 ]. In addition, recent 
tudies demonstrated that antigen-carrying γ-PGA NPs generated 
rotective antiviral and anticancer immunity, suggesting that they 
re promising vaccine candidates [ 18 , 19 ]. However, their immuno- 
ogical kinetics in vivo remains unknown. In this study, we have in- 
estigated the antigen delivery kinetics of γ-PGA NPs in mice after 
ubcutaneous injection and found that DCs capturing γ-PGA NPs mi- 
rate to the regional lymph nodes (LNs) and strongly induce cellular 
mmune responses. 
. Materials and methods 
.1. Mice 
The wild-type C57BL / 6 mice were obtained from Charles River 
apan (Yokohama, Japan). The mice were bred under speciﬁc 
athogen-free conditions in the breeding facilities of Kagoshima Uni- 
ersity. All experiments were approved by Kagoshima University and 
onducted in accordance with its guideline for animal experimenta- 
ion. 
.2. Preparation of γ -PGA NPs 
γ-PGA (average molecular weight: 380,000) was kindly provided 
y Meiji Seika (Tokyo, Japan). The synthesis of γ-PGA NPs, ﬂuores- 
ein 5-isothiocyanate (FITC)-labeled γ-PGA NPs (FITC-NPs), ovalbu- 
in (OVA)-carrying γ-PGA NPs (OVA-NPs), and FITC-labeled OVA 
FITC-OVA)-carrying γ-PGA NPs (FITC-OVA-NPs) has been described 
n our previous report [ 14 ]. The sizes of γ-PGA NPs and OVA-NPs 
n aqueous solution were measured by a dynamic light scattering 
ethod. The mean diameters of γ-PGA NPs and OVA-NPs were 210 
67 and 252 ± 92 nm, respectively. The contamination with bacte- 
ial endotoxin in γ-PGA NPs was determined by Limulus amoebocyte 
ysate assay (Seikagaku, Tokyo, Japan) and found to be less than 10 
ndotoxin units / ml. 
.3. Uptake of γ -PGA NPs by DCs in vivo 
To examine the uptake of γ-PGA NPs by DCs in vivo, FITC-NPs 
1.0 mg of γ-PGA NPs in 100 μl of phosphate-buffered saline (PBS)] 
r FITC-OVA-NPs (0.1 mg of FITC-OVA and 1.0 mg of γ-PGA NPs in 
00 μl of PBS) were subcutaneously injected to mice. The regional LNs 
nd spleen were collected from the mice and dissociated into single- 
ell suspensions. The cell-associated ﬂuorescence was measured by 
ow cytometry (FACSCalibur 
TM 
; BD Biosciences, San Jose, CA), and 
ytometric data were analyzed by CellQuestPro (BD Biosciences). To 
haracterize DCs capturing γ-PGA NPs, FITC-OVA-NPs (0.1 mg of FITC- 
VA and 1.0 mg of γ-PGA NPs in 100 μl of PBS) were subcutaneously 
njected to mice. On day 3 after injection, the LNs were collected and 
tained with an allophycocyanin-conjugated anti-CD11c monoclonal 
ntibody (mAb) and phycoerythrin (PE)-conjugated anti-CD80, anti- 
D86, anti-CCR7, and anti-CD40 mAbs (all from BD Biosciences), or 
 mAb recognizing the OVA-derived peptide (SIINFEKL) bound to the 
HC class I molecule H-2K b (eBioscience, San Diego, CA) for 30 min at 
 
◦C. After washing with PBS, the cells were analyzed by ﬂow cytom- 
try. To examine the uptake of various forms of OVA-NPs by DCs in vivo, FITC-OVA (0.1 mg of FITC-OVA in 100 μl of PBS), FITC-OVA-NPs 
(0.1 mg of FITC-OVA and 1.0 mg of γ-PGA NPs in 100 μl of PBS), or 
FITC-OVA + aluminum (Sigma, St. Louis, MO) (0.1 mg of FITC-OVA 
and 1.0 mg of aluminum in 100 μl of PBS) were subcutaneously in- 
jected to mice. The regional LNs and spleen were collected from the 
mice and dissociated into single-cell suspensions. The cells were an- 
alyzed by ﬂow cytometry. To detect CD11c + CD103 + DCs capturing 
γ-PGA NPs, FITC-OVA-NPs (0.1 mg of FITC-OVA and 1.0 mg of γ-PGA 
NPs in 100 μl of PBS) were subcutaneously injected to mice. On day 3 
after injection, the LNs were collected and stained with PE-conjugated 
anti-CD11c and allophycocyanin-conjugated anti-CD103 mAb (both 
from BD Bioscience) for 30 min at 4 ◦C. After washing with PBS, the 
cells were analyzed by ﬂow cytometry. 
2.4. Cross-presentation assay in vitro 
Bone marrow (BM)-derived DCs (BMDCs) were prepared by cul- 
turing bone marrow cells in the presence of 20 ng / ml granulocyte / 
macrophage colony stimulating factor (PeproTech, Rocky Hill, NJ), as 
previously described [ 12 ]. BMDCs (1 × 10 6 / ml) were stimulated with 
either PBS, OVA (10 μg / ml), OVA-NPs (10 μg / ml OVA and 100 μg / ml 
γ-PGA NPs), or OVA + lipopolysaccharide (LPS) (10 μg / ml OVA and 
1 μg / ml LPS) for 24 h. The cells were harvested and washed with PBS. 
Antigen-speciﬁc CD8 + T cells were obtained by the negative selection 
of splenic mononuclear cells in immunized mice with OVA-NPs using 
mAbs to Ly-76, B-220, Ly-6G, I-A / I-E, and CD4 (all from eBioscience) 
and anti-rat IgG antibody-conjugated immunomagnetic beads (Life 
Technologies, Grand Island, NY). The cells were found to be more 
than 90% pure, as determined by ﬂow cytometry after staining with 
an FITC-conjugated anti-CD8 mAb (BD Biosciences). CD8 + T cells and 
DCs were incubated in a ﬂat-bottomed 96-well plate. After incuba- 
tion for 4 days, the proliferation of CD8 + T cells was determined 
by 3 H-thymidine incorporation. 
2.5. Induction of antigen-speciﬁc CD8 + T cells in vivo 
The mice were anesthetized by an intraperitoneal injection of 
sodium pento-barbital and immunized with OVA and various ad- 
juvants. Mice were immunized once with PBS, OVA alone (10 μg), 
OVA-NPs (100 μg of NPs carrying 10 μg of OVA), or OVA + aluminum 
(10 μg of OVA and 100 μg of aluminum) by a subcutaneous route. On 
day 14 after immunization, spleen cells were collected. A PE-labeled 
tetramer recognizing the immunodominant CD8 + T-cell peptide (SI- 
INFEKL) of OVA bound to the C57BL / 6 MHC I allele H-2K b (Medical & 
Biological Laboratories, Nagoya, Japan) was used for experiments. To 
detect OVA-speciﬁc CD8 + T cells, spleen cells were stained with the 
tetramer and an FITC-conjugated anti-CD8 mAb (Beckman Coulter, 
Brea, CA). The cells were washed with PBS containing 0.1% sodium 
azide and 0.1% bovine serum albumin and ﬁxed with PBS containing 
2.5% formaldehyde (Wako, Osaka, Japan). The cell-associated ﬂuores- 
cence was measured by ﬂow cytometry. To examine the kinetics of 
OVA-speciﬁc CD8 + T cells, mice were immunized once with OVA- 
NPs (100 μg of NPs carrying 10 μg of OVA) by a subcutaneous route. 
On days 1, 3, 5, 7, 10, and 15 after immunization, spleen cells were 
collected, stained, and analyzed by ﬂow cytometry. 
2.6. Statistical analysis 
Data were analyzed for their statistical signiﬁcance by the Stu- 
dent’s t -test. 
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Fig. 1. Uptake of FITC-NPs by APCs in vivo. (A) Mice ( n = 3) were subcutaneously injected with FITC-NPs. After 3 days, cells from the regional LNs or spleen were collected and 
analyzed by ﬂow cytometry. Mice injected with PBS or FITC only were used as controls. Each number represents the percentage of FITC + cells. (B) Mice ( n = 3) were injected 
subcutaneously with FITC-NPs. Cells from the LNs or spleen were collected at the indicated time points and analyzed by ﬂow cytometry. Each number represents the percentage 
















 3. Results 
3.1. Uptake of γ -PGA NPs in vivo 
To examine the uptake of FITC-NPs by APCs in vivo, the regional
LNs and spleen were collected from mice on day 3 after subcutaneous
injection of PBS, FITC, or FITC-NPs. It is clear that the FITC + cells were
observed in the LNs obtained from the mice injected with FITC-NPs
( Fig. 1 A). In contrast, no FITC + cells were detected in the LNs obtained
from the mice injected with PBS or FITC. Furthermore, FITC + cells
were not observed in the spleen obtained from the mice injected with
PBS, FITC, or FITC-NPs. To examine the kinetics of FITC-NPs, mice were subcutaneously injected with FITC-NPs and the LNs and spleen were
collected at various time points. FITC + cells could be found in the LNs
on day 1 after injection of FITC-NPs ( Fig. 1 B). The strongest signal of
FITC + cells was detected in the LNs on day 3. Again, FITC + cells were
not observed in the spleen at any time points. These results suggest
that γ-PGA NPs are efﬁciently taken up by APCs and transported to
the regional LNs. 
3.2. Uptake of antigen-carrying γ -PGA NPs in vivo 
Targeting antigens to APCs is assumed to be an effective strat-
egy for potent induction of antigen-speciﬁc effector T cells in vaccine
development [ 7 , 8 ]. Therefore, the uptake of antigen-carrying γ-PGA
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Fig. 2. Uptake of various forms of FITC-OVA by APCs in vivo. Mice ( n = 3) were injected subcutaneously with FITC-OVA, FITC-OVA-NPs, or FITC-OVA + aluminum (AL). After 3 days, 
cells from the regional LNs or spleen were collected and analyzed by ﬂow cytometry. Mice injected with PBS were used as a control. Each number represents the percentage of 
FITC + cells. A representative result of three separate experiments is shown. 
Fig. 3. Maturation of DCs by antigen-carrying γ-PGA NPs in vivo. (A) Mice ( n = 3) were subcutaneously injected with FITC-OVA-NPs. After 3 days, cells from the regional LNs were 
isolated, stained with the anti-CD11c mAb, and analyzed by ﬂow cytometry. Mice injected with PBS were used as a control. Each number represents the percentage of cells in the 
respective gates. (B) FITC-OVA-NP −CD11c + and FITC-OVA-NP + CD11c + cells were further analyzed by the expression of CD80, CD40, CD86, and CCR7. 
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Fig. 4. Presentation of NP-associated antigens by skin-derived DCs in vivo. (A) Mice ( n = 3) were subcutaneously injected with FITC-OVA-NPs. After 3 days, cells from the regional 
LNs were isolated, stained with the anti-CD11c and anti-CD103 mAbs, and analyzed by ﬂow cytometry. Mice injected with PBS were used as a control. Each number represents 
the percentage of cells in the respective gates. (B) FITC-OVA-NPs were injected, as described above. Cells from the LNs were isolated, stained with the anti-CD11c and anti-H-2K b / 
SIINFEKL complex mAbs, and analyzed by ﬂow cytometry. Mice injected with PBS were used as a control. 























































Fig. 5. Activation of antigen-speciﬁc CD8 + T cells by antigen-carrying γ-PGA NPs in 
vitro. BMDCs were cultured with PBS, OVA, OVA-NPs, or OVA + LPS. After 24h, cells 
were collected and cocultured with autogenic OVA-speciﬁc CD8 + T cells for 4 days. 
Proliferative response was measured by 3 H-thymidine uptake. Data are expressed as 
means ± SD. Statistical analysis was carried out between the OVA-NP-treated DC group 
and other groups (* p < 0.05). Ps by APCs was investigated in vivo. The regional LNs and spleen 
ere collected from mice on day 3 after subcutaneous injection of 
BS, FITC-OVA, FITC-OVA-NPs, or FITC-OVA + aluminum. The NP- 
ssociated form of FITC-OVA was taken up by APCs much more efﬁ- 
iently than FITC-OVA alone or FITC-OVA + aluminum ( Fig. 2 ). Again, 
ITC + cells were not observed in the spleen. 
.3. Maturation of DCs by antigen-carrying γ -PGA NPs in vivo 
To analyze the uptake of antigen-carrying γ-PGA NPs by APCs 
n vivo, the regional LNs were collected from mice on day 3 after 
ubcutaneous injection of PBS or FITC-OVA-NPs. Approximately 42% 
f the FITC-NP + cells were CD11c + ( Fig. 3 A). In contrast, only 2.4% 
f FITC-NP − cells were CD11c + . Since the delivery of antigens into 
Cs followed by their maturation is a critical step for initiating the 
daptive immunity, the LN cells were examined for the expression 
f CD80, CD40, CD86, and CCR7. As shown in Fig. 3 B, the expression 
as highly upregulated in FITC-NP + CD11c + cells, as compared with 
ITC-NP −CD11c + cells. 
.4. Presentation of NP-associated antigens by skin-derived DCs in vivo 
It has recently been shown that skin-derived CD103 + DCs present 
ntigens to CD8 + T cells through the cross-presentation pathway in 
ivo [ 20 , 21 ]. Therefore, FITC-OVA-NP + cells were examined whether 
hey were CD103 + DCs. The regional LNs were collected from mice 
n day 3 after subcutaneous injection of PBS (control) or FITC-OVA- 
Ps and stained with the anti-CD11c and anti-CD103 mAbs. Among 
ITC-OVA-NP + cells, 21.8% of the cells were CD103 + CD11c + ( Fig. 
 A) in NP-injected mice. Only 0.9% of the FITC-OVA-NP + cells were 
D103 + CD11c + in PBS-injected mice, which was considered to be 
he background. To determine whether the antigen was processed and 
resented by DCs, FITC-OVA-NP + CD11c + DCs were stained with the 
Ab recognizing the antigen peptide / MHC class I complex. The ex- 
ression of the complex was much higher in FITC-OVA-NP + CD11c + 
ells than in FITC-OVA-NP + CD11c − cells ( Fig. 4 B), suggesting that the 
ntigen peptides of γ-PGA NPs can be presented by the MHC class I 
olecule of DCs (cross-presentation). 
.5. Activation of antigen-speciﬁc CD8 + T cells by antigen-carrying 
-PGA NPs in vitro 
DCs were treated with antigen-carrying γ-PGA NPs and examined 
or their ability to induce antigen-speciﬁc CD8 + T cell responses in 
itro. BMDCs were incubated with PBS, OVA, OVA-NPs, or OVA + 
PS and cocultured with OVA-speciﬁc CD8 + T cells. As shown in Fig. 
 , although BMDCs treated with OVA-NPs or OVA + LPS were able 
o induce the proliferation of OVA-speciﬁc CD8 + T cells in a dose- 
ependent fashion, BMDCs treated with OVA-NPs were a more potent 
nducer of OVA-speciﬁc CD8 + T cell proliferation than those treated 
ith OVA + LPS. In contrast, BMDCs treated with PBS or OVA alone 
ardly induced the proliferation of OVA-speciﬁc CD8 + T cells. 
.6. Activation of antigen-speciﬁc CD8 + T cells by antigen-carrying 
-PGA NPs in vivo 
To conﬁrm the activation of antigen-speciﬁc CD8 + T cells by 
ntigen-carrying γ-PGA NPs in vivo, mice were subcutaneously 
mmunized once with PBS, OVA, OVA-NPs, or OVA + aluminum. 
he number of OVA-speciﬁc CD8 + T cells was determined by the 
etramer-staining assay on day 15 after immunization. The mice im- 
unized with OVA-NPs displayed signiﬁcant increase of OVA-speciﬁc 
D8 + T cells, ( Fig. 6 A). However, such CD8 + T cells were hardly de- 
ected in mice immunized with PBS, OVA, or OVA + aluminum. To 
xamine the kinetics of OVA-speciﬁc CD8 + T cells, the cells were 
easured at various time points after immunization. OVA-speciﬁc CD8 + T cells could be identiﬁed on day 7 and did reach the peak level 
on day 10 ( Fig. 6 B). These results indicate that the immunization with 
antigen-carrying γ-PGA NPs strongly activate antigen-speciﬁc CD8 + 
T cells not only in vitro but also in vivo. 
4. Discussion 
Although particulates are widely used as antigen carriers, their 
adjuvant mechanisms in vivo are poorly understood. In this study, we 
provide the evidence that APCs migrate from the injection site to the 
regional LNs after the uptake of γ-PGA NPs in vivo. The uptake and 
presentation of antigens by APCs are essential for the induction of 
antigen-speciﬁc immune responses [ 22 ]. In a steady state, APCs cir- 
culate through peripheral tissues, where they capture antigens and 
migrate to the secondary lymphoid organs [ 23 ]. After injection with 
γ-PGA NPs (both FITC-NPs and FITC-OVA-NPs), APCs migrated to the 
regional LNs from the skin in vivo ( Figs. 1 and 2 ). In addition, NP- 
associated antigens (FITC-OVA-NPs) could enhance the antigen up- 
take by APCs than antigens alone in vivo ( Fig. 2 ). Although γ-PGA 
NPs appeared to be taken up by both CD11c + cells (DCs) and CD11c −
cells (presumably, macrophages and B cells), a considerable number 
(approximately 40%) of CD11c + cells was found to capture γ-PGA 
NPs ( Fig. 3 A). Thus, γ-PGA NPs have great potential as an effective 
antigen carrier that mainly targets DCs in vivo. 
Antigen uptake by DCs and subsequent their maturation is a key 
step for initiating and regulating the adaptive immunity [ 7 , 10 , 20 –23 ]. 
The interaction between antigen components and DCs appears to trig- 
ger off the maturation of DCs and enhance their antigen-presenting 
capacity, costimulatory molecule expression, and cytokine produc- 
tion. Our previous studies showed that γ-PGA NPs were efﬁciently 
taken up by DCs and did induce their maturation through the TLR4 
and MyD88 signaling pathway in vitro [ 12 , 15 , 24 , 25 ]. However, the 
evidence of DC maturation after uptake of γ-PGA NPs and migration 
from the skin to the regional LNs in vivo has not been demonstrated 
yet. In this study, the uptake of γ-PGA NPs by DCs resulted in their 
enhanced expression of costimulatory molecules in vivo. In addition, 
a high level of CCR7 expression was observed in DCs capturing γ- 
PGA NPs in vivo ( Figs. 2 B and 4 B). CCR7 plays important roles in DC 
migration to the LNs and the induction of maturation signals [ 23 ]. 
Mature DCs move into the regional LNs and present the pro- 
cessed antigens with the MHC class I molecule through the antigen 
cross-presentation pathway [ 7 , 10 , 21 ]. During this process, cytosolic 
proteins are hydrolyzed by the proteasome complex to yield pep- 
tides that are translocated into the endoplasmic reticulum through 
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Fig. 6. Activation of antigen-speciﬁc CD8 + T cells by antigen-carrying γ-PGA NPs in vivo. (A) Mice were subcutaneously injected once with PBS, OVA, OVA-NPs, or OVA + AL 
(aluminum). Spleen cells were isolated on day 15 after immunization. The cells were stained with the anti-CD8 mAb and H-2K b / OVA 257–264 tetramer. Data are expressed as the 
percentages of pentamer-binding CD8 + T cells among the gated CD8 + T cells, as determined by ﬂow cytometry. The experiments were performed for three mice per each group, 
and data represent means ± SD in each group. Statistical analysis was carried out among the 4 groups (* p < 0.05). (B) Mice were subcutaneously injected once with OVA-NPs. 
Spleen cells were isolated at the indicated time points. OVA-speciﬁc CD8 + T cells were analyzed, as described above. The experiments were performed for three mice per each 
group, and data represent means ± SD in each group. Statistical analysis was carried out between the day 1 group and other groups (* p < 0.05). 




























































r transporter associated with antigen presentation. In the endoplas- 
ic reticulum, the peptides bind to the MHC class I molecule and 
re transported to the cell surface for recognition by CD8 + T cells 
 26 ]. In fact, it has been shown that γ-PGA NPs release carrying anti- 
ens to the cytoplasm of DCs [ 27 ]. DCs migrating from the skin could 
resent OVA-derived peptides by the MHC class I molecule after sub- 
utaneous injection of FITC-OVA-NPs ( Fig. 4 B). Furthermore, BMDCs 
reated with OVA-NPs stimulated OVA-speciﬁc CD8 + T cells in vitro 
 Fig. 5 ). Skin-derived CD103 + DCs are considered to be essential for 
he cross-presentation of antigens to CD8 + T cells [ 20 , 21 ]. Therefore, 
he uptake of antigens by CD103 + DCs is important for cognate T cells 
o differentiate into antigen-speciﬁc CD8 + T cells. CD103 + DCs cap- 
uring γ-PGA NPs were found in the regional LNs after subcutaneous 
njection with γ-PGA NPs ( Fig. 4 A). Taken together, antigen-carrying 
Ps are taken up by CD103 + DCs and present NP-associated antigens 
o CD8 + T cells in vivo. 
Activation of the cytolytic immune response that clears infected 
ost cells is a key area of research for improving vaccines [ 1 ]. The 
daptive cytolytic response is primarily mediated by CD8 + T cells 
 28 , 29 ]. CD8 + T cells can fulﬁll direct destruction of infected cells 
ia recognition of pathogen-derived antigens presented in the con- 
ext of MHC class I. The generation of antigen-speciﬁc CD8 + T cells 
s most likely mediated by cross-presenting DCs [ 30 , 31 ]. Our pre- 
ious studies showed that antigen-speciﬁc CD8 + T cells induced by 
ntigen-carrying γ-PGA NPs differentiated to the memory phenotype 
nd remained stable for a long period of time [ 13 , 15 ]. Although one 
f the important aspects in vaccine development is rapid induction of 
ntigen-speciﬁc CD8 + T cells, the kinetics of antigen-speciﬁc CD8 + 
 cells generated by immunization with γ-PGA NPs remains to be 
lucidated. In this study, a signiﬁcant level of OVA-speciﬁc CD8 + T 
ells was detected on day 7 after single immunization with OVA-NPs. 
hese ﬁndings suggest that antigen-carrying NPs can induce rapidly 
he antigen-speciﬁc effector and long-lived memory CD8 + T cells in 
ivo. 
Most vaccines developed so far are live-attenuated, inactivated, 
nd subunit ones [ 15 ]. Live-attenuated vaccines have an advantage 
f inducing both humoral and cellular immune responses. However, 
ive-attenuated vaccines can still infect and replicate in the hosts, 
hereby their safety is difﬁcult to control. Inactivated and subunit 
accines induce only humoral immunity and require multiple doses. 
specially, subunit vaccines are poorly immunogenic and require a 
ooster vaccination every few years. Therefore, a number of DNA 
accines capable of inducing humoral and cellular immune responses 
re currently under investigation [ 32 ]. In addition, a lot of attempts 
ave been made to develop effective vaccine adjuvants [ 2 , 33 ]. In this 
egard, γ-PGA NPs are capable of inducing both humoral and cellular 
mmune responses [ 12 –19 ]. In addition, various proteins, peptides, 
nd chemicals can be encapsulated into the particles and / or immobi- 
ized onto their surfaces [ 14 ]. The injection of antigens in combination 
ith γ-PGA NPs has been shown to enhance not only antigen uptake 
ut also DC maturation in vivo. Thus, it is possible that combinations 
f other immunization techniques such as DNA vaccines with γ-PGA 
Ps are more effective for inducing antigen-speciﬁc humoral and cel- 
ular immune responses. 
. Conclusion 
The present results clearly show that DCs capturing γ-PGA NPs 
igrate into the regional LNs from their injection site. In addition, 
ntigen-carrying γ-PGA NPs promote the maturation of DCs and 
nduce cross-presentation of antigens by the MHC class I molecule 
f DCs. Furthermore, single immunization with antigen-carrying γ- 
GA NPs induces rapid activation of antigen-speciﬁc CD8 + T cells. 
herefore, γ-PGA NPs can effectively induce the adaptive immune 
esponses through the DC-mediated immune system in vivo and may have great potential as an antigen-delivery system and vaccine adju- 
vant. 
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